Formulary guidance and transparency from P&T to point of care

Trends that Matter for Biosimilars and Orphan Drugs

Posted by Matt Breese on Jan 8, 2016

Find me on:

A collection of engaging infographics from healthcare influencers to capture trends in emerging groups of pharmaceuticals, like biosimilars and orphan drugs.

U.S. retail pharmacies only distribute 5% of biologics on the market, according to the AfPA


Via Alliance for Patient Access


A staggering 95% of rare diseases have no approved pharmaceutical treatment in certain markets


Via Orphan Drug 101


21 blockbuster biopharmaceutical products, representing $50 billion of annual market value, go off patent between 2009 and 2019


Via ISR Reports


While orphan drugs treat rare diseases for less than 200,000 people in the U.S. according to ISR, the market represents a significant opportunity for biopharma manufacturers


Check Out the Full Piece on Drug Development Trends Here


Follow us on Twitter to stay current with new biosimilar and orphan drug developments.

Follow MMIT on Twitter

Topics: Industry Trends, Market Access